Immunoprophylaxis of 100% was achieved in newborn infants at 7months of follow-up. be unfavorable for HBV.Conclusion.PEP achieved 100% efficacy among infants who complied with the study protocol at 7 months of follow-up. The prevalence of hepatitis B among pregnant women was 8 per 1000 live births. Keywords:hepatitis B virus, vertical transmission, immuno-prophylaxis, vaccination, prevention strategies, Saudi Arabia == Introduction == Chronic hepatitis B virus (HBV) infection is usually estimated to affect approximately 240 to 360 million people worldwide and almost a third of the worlds population presents with the historical evidence of hepatitis contamination which ranks 15th and has a substantial morbidity and mortality, primarily via chronic infection. 1People who are chronically infected with HBV are at risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC).2,3Since the virus is detected in all body fluids such as serum, urine, breast milk, saliva, urine, tears, vaginal secretions, menstrual blood, and semen, its transmission can be via perinatal, percutaneous, close contact through open cuts and sores, sexual intercourse etc.4,5 The most common method of transmission of HBV is perinatal transmission at birth or horizontal transmission to/between young children.6The risk of perinatal transmission is associated with 4 important factors (i) hepatitis Be Ag status of the mother, (ii) serum HBs Protostemonine levels, (iii) HBV viral load, and (iv) earlier age of pregnancy.7,8It has been demonstrated that this rate of vertical transmission of contamination in children from HBeAg-positive women ranges from 70% to 90% in comparison to only 32% for HBeAg-negative women.2,9 The World Health Organization (WHO) via its Global Health Sector Strategy aims to decrease the Rabbit polyclonal to ANTXR1 HBV prevalence to <0.1% in children below 5 years of age.10,11Thus, preventing the vertical transmission of the infection is critical and is based on the following 3 pillars: (i) Administration of timely HBV vaccine (within 24 hours) to a newborn and follow up with at least 3 doses to complete the primary series, regardless of the HBsAg status of the pregnant mother, (ii) effective screening of pregnant women for HBsAg and administration of hepatitis B immunoglobulin (HBIG) to infants born to HBsAg-positive and HBeAg-positive mothers, and (iii) antiviral prophylaxis in pregnant women with HBV DNA200,000 IU/mL.11-13 The Saudi Arabian vaccination program has added HBVac as the seventh primary immunogenic since 1989, ensuring that all newborn infants are duly vaccinated at the time of birth; however, the population aged above 30 years is still regarded as a risk group and there is a gap in HBV care which needs to be screened proactively.14-16In Saudi Arabia, the prevalence of HBV has witnessed a dramatic decline over the last 3 decades with the establishment of the HBV immunization program,17and it has been reported to be 1.7% which is lower than the worldwide prevalence of 3.6%.18-20Furthermore, owing to the universal childhood vaccination program, the prevalence of chronic HBV infection in the younger Saudi population (<30 years) is estimated to be <0.5%.20,21 The aim of this study was to assess compliance with the administration of the PEP as per the standard protocol and to report the outcomes of adherence to the recommended guidelines for PEP. The following objectives were kept in mind when carrying out this study: to evaluate the efficacy and compliance of postexposure prophylaxis (PEP) among infants and compare the efficacy of PEP to the international conversion rates. == Methods == == Study Design == This was a retrospective cohort study designed and performed at King Abdulaziz Medical City, Jeddah and was carried out between June 2016 and May 2020 (4 years). == Ethical Approval == The study was approved by the Institutional Review Board (IRB;RJ20-044-J) committee of the University. The chart review of the electronic medical records from the patient care and hospital information system (BestCare) was done. Written informed consent from participating subjects and or their guardians Protostemonine was taken as per Helsinki principles. == Sampling == All pregnant mothers who were HBsAg positive at the time of delivering their newborn infants at KAMC, Jeddah, were included in the analysis. All live newborn infants whose mothers were HBsAg positive and subsequently planned to receive the hepatitis B vaccine (HBVac) and hepatitis B immunoglobulin (HBIG) within 12 hours of birth Protostemonine were included in this study. The newborn infants who failed Protostemonine to complete the vaccination protocol at 2, 4, and 6 months as per standard vaccination guidelines were excluded from the study. Serologic testing of babies, using chemiluminescent micro particle immunoassay (ABBOTT Alinity, UK), was carried out at 7 months using HBsAg and anti-HBs titers after the completion of 3 doses of vaccine. The sensitivity of the test is 100% as compared to PCR. The standard protocol followed in the Pediatric Department is.